A phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: Background and rationale of the Radiotherapy - Adjuvant Versus Early Salvage (RAVES) trial

BJU International

Volumn 113, Issue SUPPL. 2, 2014, Pages 7-12

  Pearse, Maria ^a   Fraser Browne, Carol ^a   Davis, Ian D ^b   Duchesne, Gillian M ^c   Fisher, Richard ^d   Frydenberg, Mark ^f   Haworth, Annette ^e   Jose, Chakiath ^a   Joseph, David J ^g   Lim, Tee S ^h   Matthews, John ^a   Millar, Jeremy ^c   Sidhom, Mark ⁱ   Spry, Nigel A ^g   Tang, Colin I ^g   Turner, Sandra ^j   Williams, Scott G ^c   Wiltshire, Kirsty ^c   Woo, Henry H ^k   Kneebone, Andrew ^l  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

^b MONASH UNIVERSITY   (Australia)

^c Monash University ^*  (Australia)

^d Centre for Biostatistics and Clinical Trials   (Australia)

^e PETER MACCALLUM CANCER CENTRE   (Australia)

^f MONASH MEDICAL CENTRE   (Australia)

^g SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^h ROYAL PERTH HOSPITAL   (Australia)

ⁱ LIVERPOOL HOSPITAL   (Australia)

^j Westmead and Nepean Hospitals   (Australia)

^k UNIVERSITY OF SYDNEY   (Australia)

^l SYDNEY CANCER CENTRE   (Australia)

more..

Author keywords

Adjuvant radiation therapy; Post prostatectomy radiation therapy; Prostate cancer; Radical prostatectomy; RAVES trial; Salvage radiation therapy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADVERSE OUTCOME; ARTICLE; BIOCHEMICAL FAILURE FREE SURVIVAL; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SALVAGE THERAPY; SURVIVAL RATE; SURVIVAL TIME; ADENOCARCINOMA; ADJUVANT RADIATION THERAPY; ADJUVANT THERAPY; AUSTRALIA; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; MALE; METHODOLOGY; NEW ZEALAND; PATHOLOGY; POST-PROSTATECTOMY RADIATION THERAPY; PROSTATE TUMOR; PROSTATECTOMY; RAVES TRIAL; RISK ASSESSMENT; SALVAGE RADIATION THERAPY; TIME; TREATMENT OUTCOME; TUMOR INVASION;

ADJUVANT RADIATION THERAPY; POST-PROSTATECTOMY RADIATION THERAPY; PROSTATE CANCER; RADICAL PROSTATECTOMY; RAVES TRIAL; SALVAGE RADIATION THERAPY;

ADENOCARCINOMA; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; AUSTRALIA; DISEASE-FREE SURVIVAL; HUMANS; MALE; NEOPLASM INVASIVENESS; NEW ZEALAND; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; RISK ASSESSMENT; SALVAGE THERAPY; TIME FACTORS; TREATMENT OUTCOME;

EID: 84904041507     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12623     Document Type: Article

References (14)

1. Bolla M, van Poppel H, Tombal B et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet 2012; 380: 2018-27
2. Thompson IM, Tangen CM, Paradelo J et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 2009; 181: 956-62
3. Wiegel T, Bottke D, Steiner U et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 2009; 27: 2924-30
4. Sidhom MA, Kneebone AB, Lehman M et al. Post-prostatectomy radiation therapy: consensus guidelines of the Australian and New Zealand Radiation Oncology Genito-Urinary Group. Radiother Oncol 2008; 88: 10-9
5. Sundaresan P, Turner S, Kneebone A, Pearse M, Butow P. Evaluating the utility of a patient decision aid for potential participants of a prostate cancer trial (RAVES-TROG 08.03). Radiother Oncol 2011; 101:521-4
6. Collette L, van Poppel H, Bolla M et al.; European Organisation for Research and Treatment of Cancer (EORTC) Radiotherapy and Genito-urinary Group. Patients at high risk of progression after radical prostatectomy: do they all benefit from immediate post-operative irradiation? (EORTC trial 22911). Eur J Cancer 2005; 41: 2662-72
7. Thompson IM Jr, Tangen CM, Paradelo J et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 2006; 296: 2329-35
8. Feng M, Hanlon AL, Pisansky TM et al. Predictive factors for late genitourinary and gastrointestinal toxicity in patients with prostate cancertreated with adjuvant or salvage radiotherapy. Int J Radiation Biol Phys 2007; 68: 1417-23
9. Stephenson AJ, Scardino PT, Kattan MW et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007; 25: 2035-41
10. Briganti A, Wiegel T, Joniau S et al. Early salvage radiation therapy doesnot compromise cancer control in patients with pT3N0 prostate cancer after radical prostatectomy: results of a match-controlled multi-institutional analysis. Eur Urol 2012; 62: 472-87
11. Budiharto T, Perneel C, Haustermans K et al. A multi-institutional analysis comparing adjuvant and salvage radiation therapy for high-risk prostate cancer patients with undetectable PSA after prostatectomy. Radiother Oncol 2010; 97: 474-9
12. Trock BJ, Misop H, Freedland SJ et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemicalrecurrence after radical prostatectomy. JAMA 2008; 299: 2760-9
13. Stephenson AJ, Eggener SE, Hernandez AV et al. Do margins matter? The influence of positive surgical margins on prostate cancer-specific mortality. Eur Urol 2013; doi: 10.1016/j.eururo.2013.08.036 [Epub aheadof print]
14. Moinpour CM, Hayden KA, Unger JM et al. Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy. J Clin Oncol 2008; 26: 112-20